The present invention relates to methods for predicting and evaluating metastasis of solid cancers, such as melanoma, in a subject by measuring serum biomarkers associated with a metastatic phenotype. In particular, the present invention provides a serum gene expression signature that is different between highly aggressive and more metastatic versus less aggressive and less metastatic melanomas by quantitatively measuring the levels of, inter alia, lymphoid-specific helicase (HELLS) and condensing complex subunit 2 (NCAPH) transcripts in a subject.
GOVERNMENT INTEREST STATEMENT
 This invention was made with government support under grant number NIH K01 CA113779 awarded by the National Institutes of Health, Nevada Cancer Institute (NVCI) Startup Grant, and DOE DE-FG01-08ER64608 grant awarded by the Department of Energy. The government has certain rights in the invention.